Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Assets Average (2020 - 2025)

Historic Assets Average for Nurix Therapeutics (NRIX) over the last 6 years, with Q4 2025 value amounting to $605.3 million.

  • Nurix Therapeutics' Assets Average rose 233.86% to $605.3 million in Q4 2025 from the same period last year, while for Nov 2025 it was $605.3 million, marking a year-over-year increase of 233.86%. This contributed to the annual value of $678.7 million for FY2025, which is 3244.45% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Assets Average of $605.3 million as of Q4 2025, which was up 233.86% from $557.0 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Assets Average registered a high of $642.2 million during Q1 2025, and its lowest value of $329.4 million during Q3 2023.
  • Over the past 5 years, Nurix Therapeutics' median Assets Average value was $447.6 million (recorded in 2022), while the average stood at $462.8 million.
  • Per our database at Business Quant, Nurix Therapeutics' Assets Average crashed by 2423.29% in 2023 and then soared by 9219.51% in 2025.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Assets Average stood at $484.9 million in 2021, then dropped by 9.67% to $438.0 million in 2022, then decreased by 24.23% to $331.9 million in 2023, then skyrocketed by 78.21% to $591.5 million in 2024, then rose by 2.34% to $605.3 million in 2025.
  • Its Assets Average was $605.3 million in Q4 2025, compared to $557.0 million in Q3 2025 and $603.3 million in Q2 2025.